Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type

Lung Cancer

Volumn 76, Issue 2, 2012, Pages 197-203

  Lee, Geon Kook ^a   Lee, Hee Seok ^a   Park, Young Seung ^b   Lee, Jeong Hwa ^c   Lee, Seok Cheol ^a   Lee, Jong Ho ^c   Lee, Soo Jae ^c   Shanta, Selina Rahman ^c   Park, Hye Min ^a   Kim, Hyo Rim ^a   Kim, In Hoo ^a   Kim, Young Hwan ^b,d   Zo, Jae Ill ^a   Kim, Kwang Pyo ^c   Kim, Hark Kyun ^a  

^a National Cancer Center   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Konkuk University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

Histologic type; Histology directed MALDI; Lipid; Lung cancer; Phosphatidylcholine

Indexed keywords

ALPHA CYANO 4 HYDROXYCINNAMIC ACID; GENTISIC ACID; PHOSPHATIDYLCHOLINE;

ACCURACY; ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; VALIDATION PROCESS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELLS; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859432493     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.016     Document Type: Article

References (20)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010, 36(Suppl. 3):S21-S29.
3. Yanagisawa K., Shyr Y., Xu B.J., Massion P.P., Larsen P.H., White B.C., et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003, 362(9382):433-439.
4. Kim H.K., Reyzer M.L., Choi I.J., Kim C.G., Kim H.S., Oshima A., et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010, 9(8):4123-4130.
5. Jackson S.N., Woods A.S. Direct profiling of tissue lipids by MALDI-TOFMS. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(26):2822-2829.
6. Shanta S.R., Zhou L.H., Park Y.S., Kim Y.H., Kim Y., Kim K.P. Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal Chem 2011, 83(4):1252-1259.
7. Meriaux C., Franck J., Wisztorski M., Salzet M., Fournier I. Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids. J Proteomics 2010, 73(6):1204-1218.
8. Momchilova A., Markovska T., Pankov R. Phospholipid dependence of membrane-bound phospholipase A2 in ras-transformed NIH 3T3 fibroblasts. Biochimie 1998, 80(12):1055-1062.
9. Simon R., Lam A., Li M.C., Ngan M., Menenzes S., Zhao Y. Analysis of gene expression data using BRB-Array Tools. Cancer Inform 2007, 2:11-17.
10. Momchilova A.B., Petkova D.H., Koumanov K.S. Phospholipid composition modifications influence phospholipase A2 activity in rat liver plasma membranes. Int J Biochem 1986, 18:945-952.
11. Janardhan S., Srivani P., Sastry G.N. Choline kinase: an important target for cancer. Curr Med Chem 2006, 13(10):1169-1186.
12. Gallego-Ortega D., Ramirez de Molina A., Ramos M.A., Valdes-Mora F., Barderas M.G., Sarmentero-Estrada J., et al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009, 4(11):e7819-e7829.
13. Duarte I.F., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours?. Virchows Arch 2010, 457(6):715-725.
14. Borczuk A.C., Gorenstein L., Walter K.L., Assaad A.A., Wang L., Powell C.A. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163(5):1949-1960.
15. Khoor A., Whitsett J.A., Stahlman M.T., Olson S.J., Cagle P.T. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999, 30(6):695-700.
16. Veldhuizen R., Nag K., Orgeig S., Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998, 1408:90-108.
17. Bernhard W., Wang J.Y., Tschernig T., Tümmler B., Hedrich H.J., von der Hardt H. Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HG/m1HGU mice. Thorax 1997, 52:723-730.
18. Berry K.A., Li B., Reynolds S.D., Barkley R.M., Gijón M.A., Hankin J.A., et al. MALDI imaging MS of phospholipids in the mouse lung. J Lipid Res 2011, 52(8):1551-1560.
19. Terry J., Leung S., Laskin J., Leslie K.O., Gown A.M., Ionescu D.N. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010, 34(12):1805-1811.
20. Mukhopadhyay S., Katzenstein A.L. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011, 35(1):15-25.